Registro de fecundación in vitro e inyección espermática intracitoplasmática de la Sociedad Española de Fertilidad de los años 2010 y 2011

Prados, Fernando; Vidal, Ester; Hernández, Juana; Marqueta, J.; Herrero, Julio; Cabello, Yolanda; Santos, María José de los; Buxaderas, Rosario; Segura, Ana; Zamora, Sandra; Andrés, Montserrat de; Cuevas, Irene; Castilla, José Antonio

doi:10.1016/j.medre.2014.09.001

Cited by 6 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of the strengths of the present study is that it takes into account the PURSUE study, where age is the determining factor for both the specific dose of gonadotropin and the results of efficacy outcomes ( Boostanfar et al, 2015 ). Age is a variable of particular interest in controlled ovarian stimulation within ART, as it influences the clinical outcomes and the economic consequences ( Bouwmans et al, 2008 , Prados et al, 2014 , Ruiz-Balda et al, 2005 ). Therefore, it is important to assess the economic impact in older patients to allow more personalized care.…”

Section: Discussionmentioning

confidence: 99%

“…In Spain, intracytoplasmatic sperm injection (ICSI) is the most common procedure for in-vitro fertilization (IVF) ( Matorras, 2011 , Sunyer and Almazán, 2012 ). Most treatments in Spain are performed in private centres ( Prados et al, 2014 ). The Registry of the Spanish Fertility Society (Sociedad Española de Fertilidad, SEF) records most IVF (traditional) or ICSI (mixed) cycles performed in Spain ( Prados et al, 2014 ).…”

Section: Introductionmentioning

confidence: 99%

“…Most treatments in Spain are performed in private centres ( Prados et al, 2014 ). The Registry of the Spanish Fertility Society (Sociedad Española de Fertilidad, SEF) records most IVF (traditional) or ICSI (mixed) cycles performed in Spain ( Prados et al, 2014 ). Based on the latest information available in the SEF Registry, 51,591 cycles using IVF/ICSI and the patient’s own oocytes were started in Spain in 2014 ( SEF Registry, 2014 ).…”

Section: Introductionmentioning

confidence: 99%

“…The most recent direct evidence comes from the PURSUE study ( Boostanfar et al, 2015 ), where a single subcutaneous injection of 150 μg corifollitropin alfa was compared with the daily administration of 300 IU rFSH in a trial involving 1,390 women aged between 35 and 42 years. This age group is representative of the majority of patients seeking ART treatment in developed countries ( Audibert and Glass, 2015 , Prados et al, 2014 , Sociedad Española de Fertilidad (SEF) Registry, 2014 ). Treatment with corifollitropin alfa showed non-inferiority in pregnancy rates [estimated difference -3.0% (confidence interval (CI) -7.4 to 1.4)], in the mean number of oocytes recovered [estimated difference 0.5 (CI -0.2 to 1.2)] and in the rate of live births [estimated difference -2.3% (CI -6.5 to 1.9)] ( Boostanfar et al, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study

Barrenetxea¹,

García-Velasco²,

Aragón³

et al. 2018

Reproductive Biomedicine & Society Online

View full text Add to dashboard Cite

This study presents an economic assessment of controlled ovarian stimulation in assisted reproductive technology procedures in Spain, comparing the use of corifollitropin alfa and various forms of recombinant follicle-stimulating hormone (rFSH) in women of advanced maternal age. A cost-minimization analysis (CMA) was performed to assess the cost per cycle of controlled controlled ovarian stimulation, including only direct costs associated with the stimulation phase. The CMA was based on the population characteristics, the protocol, and the results obtained from the PURSUE study, taking into account 9 days of controlled controlled ovarian stimulation and 300 IU rFSH/day. The primary analysis included pharmacological costs alone. Different scenarios were evaluated including various doses and possible additional days (0–5) for rFSH. For the alternative analyses, the total costs (direct pharmacological costs, costs of visits and follow-up tests, and any additional pharmacological costs) were considered in both the private and public sectors. Treatment with corifollitropin alfa resulted in a lower pharmacological cost compared with rFSH (€757.25 and €950.30, respectively), creating a saving of approximately -20%. The results of the scenario analyses showed that corifollitropin alfa reduced the pharmacological cost of controlled ovarian stimulation in comparison with daily administration of doses ≥ 250 IU rFSH (considering same daily dose for all days), regardless of the additional days required (7–12 days) (average -€223; range -€488 to -€44). In conclusion, in addition to the efficacy shown in the PURSUE study, the use of corifollitropin alfa results in a decrease in the direct costs associated with controlled ovarian stimulation in older women in Spain.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study

Barrenetxea¹,

García-Velasco²,

Aragón³

et al. 2018

Reproductive Biomedicine & Society Online

View full text Add to dashboard Cite

show abstract

“…En análisis anteriores sobre la evolución de la fecundación in vitro en España se ha abordado el aumento en su uso así como la eficacia de las diferentes variantes de la misma (Orozco et al, 2013;Prados et al, 2014). Sin embargo, apenas existen investigaciones, tanto a nivel nacional o internacional, que aborden de manera conjunta los determinantes socioeconómicos, culturales y sociodemográficos que puedan incidir en el fenómeno.…”

Section: Conclusionesunclassified

Concilia o revienta: determinantes socioeconómicos y demográficos del uso de técnicas de reproducción humana asistida en perspectiva territorial

Martínez

Díaz

2019

Política Soc.

View full text Add to dashboard Cite

Resumen. Durante las últimas dos décadas ha crecido notablemente el número de mujeres que recurren a tratamientos de fertilidad y técnicas de reproducción humana asistida (en adelante TRHA). El aumento en la recurrencia a estas técnicas ha tratado de ser explicado en el ámbito de las ciencias de la salud a través de variables biológicas, genéticas y fenotípicas, pero apenas existen estudios que pongan de relevancia la influencia de factores socioeconómicos y demográficos para explicar el creciente uso de las TRHA. El presente artículo tiene por objeto indagar en el peso de distintas variables de carácter sociodemográfico y económico en la prevalencia del uso de las TRHA en las comunidades autónomas españolas. Para ello, a través de los datos de la Sociedad Española de Fertilidad, se ha analizado la influencia de factores como la tasa de actividad femenina, la edad media al primer matrimonio, la edad media al primer hijo, la tasa de fecundidad, el número medio de hijos por mujer, el nivel de estudios de las mujeres, o la tasa de empleo femenina en el número de ciclos de fecundación in vitro por cada mil mujeres en cada una de las comunidades autónomas. Los resultados muestran una relación directa y positiva de factores como la tasa de actividad femenina, la tasa de empleo femenino y el nivel de estudios de la población femenina. Asimismo, existe una relación de factores sociodemográficos como la edad media al matrimonio, la edad media al nacimiento del primer hijo, la tasa de fecundidad, o el número medio de hijos por mujer. Los resultados ponen de manifiesto una importancia crucial de los factores sociodemográficos y económicos en la recurrencia al uso de técnicas de reproducción humana asistida así como la necesidad de políticas de conciliación que permitan un adelanto en la edad de nacimiento del primer hijo. Palabras clave: fecundación in vitro; fertilidad; fecundidad; condicionantes socioeconómicos.[en] Promoting work-life balance or collapsing: socioeconomic and demographic factors influencing on the use of Assited Human Reproduction Techniques in regional perspective Abstract. During the last two decades the number of women who turn to fertility treatments and Assisted Human Reproduction techniques (AHRT) has notably increased. Medical Sciences have tried to explain the increasement of the use of these techniques throughout various variables such as biological factors, genetics and phenotypes, however, there are barely studies that manifest the 1 Universidad de Murcia (España). Polít. Soc. (Madr.) 56(3) 2019: 583-601 583 584 Bote, M. y A.L. Martínez-Martínez Polít. Soc. (Madr.) 56(3) 2019: 583-601relevance of socioeconomics and demographic factors to give an explanation on the actual increasement of the use of the AHRT. This article aims to inquire into the importance of several sociodemographic and economic variables in the prevalence of the use of the AHRT in the Spanish Regions. To do so, the Spanish Society of Fertility data file has been used. The influence of some factors, such as the feminine activit...

show abstract

Indicadores de calidad del laboratorio de reproducción: Manual de Buena Práctica Clínica de la SEF versus Grupo de Interés de Calidad de ASEBIR

Iglesias

Gonzálvo

Clavero

et al. 2017

Medicina Reproductiva y Embriología Clínica

View full text Add to dashboard Cite

Registro de fecundación in vitro e inyección espermática intracitoplasmática de la Sociedad Española de Fertilidad de los años 2010 y 2011

Cited by 6 publications

References 4 publications

Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study

Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study

Concilia o revienta: determinantes socioeconómicos y demográficos del uso de técnicas de reproducción humana asistida en perspectiva territorial

Indicadores de calidad del laboratorio de reproducción: Manual de Buena Práctica Clínica de la SEF versus Grupo de Interés de Calidad de ASEBIR

Contact Info

Product

Resources

About